UnitedHealth Shows Stronger Fundamentals Than Humana on Valuation and Profitability Metrics

Health insurance giants UnitedHealth Group (UNH) and Humana (HUM) are trading at nearly identical stock prices, but an analysis of their financial data reveals a stark divergence in fundamental strength and investor sentiment. According to data from September 22, 2026, UnitedHealth demonstrates superior profitability, a more attractive valuation, and stronger earnings momentum compared to Humana.

Valuation and Profitability Diverge

While both companies have seen revenue growth, their profitability and valuation metrics tell different stories. UnitedHealth, with a market capitalization of $338.90 billion, is substantially larger than Humana at $45.46 billion.

More critically, UnitedHealth appears more attractively valued and profitable. The company's return on equity (ROE) stands at 14.6%, more than double Humana's 6.8%. On a forward-looking basis, UnitedHealth trades at a price-to-earnings (P/E) ratio of 18.9x, significantly lower than Humana's 42.3x, suggesting a more favorable valuation relative to expected earnings.

A Clear Split in Earnings Momentum

The most recent earnings cycle highlights a significant gap in performance and subsequent market reaction. UnitedHealth's results and analyst revisions point to a much stronger operational footing.

Ad

• Q2 2026 Earnings: UnitedHealth beat earnings per share (EPS) estimates by a substantial 31.55%, while Humana delivered a narrower 5.26% beat.
• Stock Reaction: Following the results, UNH stock saw a positive 1.81% price reaction, whereas HUM stock fell 5.67%.
• Analyst Revisions: Over the past 90 days, consensus EPS estimates for UnitedHealth have risen 11.20%. In sharp contrast, estimates for Humana have been revised downward by a dramatic 490.75%.

Market Performance vs. Fundamentals

Despite its weaker fundamentals, Humana's stock has staged a powerful recovery, gaining 118.89% over the last six months, far outpacing UnitedHealth's 35.68% rise. This rally suggests investors have already priced in significant optimism for a turnaround at Humana.

For investors, the data presents a choice between two distinct profiles. UnitedHealth offers a stronger position based on current quality, profitability, and valuation metrics. Humana, on the other hand, represents a higher-risk recovery play, with its recent stock performance running well ahead of its challenged earnings picture.